Phospholipid Research Center Heidelberg’s Post

Dear researchers, I am glad to announce the paper entitled “Effects of plant protease inhibitors (Pep-3-EcTI, Pep-BbKI, and Pep-BrTI) versus corticosteroids on inflammation, remodeling, and oxidative stress in an asthma-COPD (ACO) model” was accepted for publication! I would to acknowledge all reviewers and authors for their hard work! Warm regards, Alan de Aguiar Lopes, Ph.D. Guest Associate Editor Frontiers in Pharmacology https://lnkd.in/eDtvaXE9 #research #academicresearch #pharmacology #respiratorydiseases #treatment #biology #frontiers

Cinnamon bark oil is a food additive and known to be safe. It is touted to be anti-inflammatory with several other wonderful properties including great smell. Its component cinnamaldehyde (doesn't it sound like a made-up funny name). A novel nanoparticle system, called ROS-CA-NPs, which is formed using polymer-cinnamaldehyde (CA) conjugates and it is responsive to reactive oxygen species (ROS). This system (a pro drug) reportedly exhibits excellent drug stability, tissue selectivity, and controlled drug release upon oxidative stress activation. Using mouse models of chronic rheumatoid arthritis and acute ulcerative colitis, the scientists demonstrated that the ROS-CA-NPs have excellent biocompatibility, and their systemic administration results in their accumulation at inflamed lesions, leading to greater therapeutic efficacy compared to traditional drugs. These findings suggest that ROS-CA-NPs have the potential to be safe and effective nanotherapeutic agents in a broad range of inflammatory diseases. #Cinnamaldehyde #NanotherapeuticAgent #RheumatoidArthritis

Source: Analytical biochemistry This article discusses different methodologies for measuring the activity of prolidase, an enzyme involved in various physiological and pathological processes. These methodologies include colorimetric and spectrophotometric assays, capillary electrophoresis, mass spectrometry, thin layer chromatography, and high-performance liquid chromatography. The accurate determination of prolidase activity is important for clinical diagnosis and therapy in conditions where proline levels are affected. The article provides an overview of these methods, their advantages, drawbacks, and suggests further research in this area.

CPN is thrilled to announce the publication of our recent research article in the esteemed journal, Journal of Molecular Liquids. Systemic delivery of Etodolac (ETO) is often accompanied by significant side effects, including myocardial issues and bleeding, which restrict its clinical application. Our research introduces a choline geranate ionic liquid-based transdermal gel (CAGE Ionogel) designed to overcome these challenges. Key findings include: ·      19,600x solubility enhancement-CAGE IL dramatically enhances ETO's solubility. ·      Enhanced permeation & sustained release- Achieves a 1.3-fold higher flux and sustained release up to 48 hours compared to conventional ETO gels. ·      Improved safety profile- Demonstrates reduced cytotoxicity (IC50 ~2.17), no significant biomarker changes, and excellent skin compatibility with low TEWL. ·      Improved antirheumatic activity These results highlight the potential of CAGE Ionogel as a safer, more effective transdermal ETO therapy for mitigating RA symptoms. You may access and share the full article before October 22, 2024, using the following link: https://lnkd.in/gAFz6ZmC #CPNlab #PharmaceuticalResearch #TransdermalDelivery #Etodolac #RheumatoidArthritis #Nanomedicine #DrugDeliveryInnovation

Autologous cytokine rich serum (ACRS) is derived from whole blood and is preferentially enriched with growth factors and cytokines, specifically the anti-inflammatory compound interleukin-1 receptor antagonist (IL-1Ra). Thus, ACRS is a powerful biologic for fighting inflammation of any kind including degenerative joint wear (OA) and skin inflammation. To watch IL-1Ra in action, please visit our website https://lnkd.in/gFEnbZv7 #PRP; #regenerativemedicine; #orthobiologics #PlateletRichPlasma; #mdbiologix; #HarvestPRP; #painmanagement

I am happy to share our work that was published today in ACS Pharmacology & Translational Science 💊 Our team has de-novo designed a new Antimicrobial peptides (#AMPs)/Host Defense Peptides (#HDPs) class offering a groundbreaking approach to sepsis prevention. By fine-tuning specific parameters, such as peptide length and positive charge placement, we successfully decoupled the antimicrobial properties from endotoxin neutralization activity. This innovation resulted in the complete rescue of mice from severe septic shock in multiple models. https://lnkd.in/dNAdKv74 Avner Fink, Naiem Wani, Hadar Cohen, Ph.D, Li-av Segev-Zarko, Chris Arnusch, Yechiel Shai #peptides #drugdiscovery #innovation #sepsis

Plasminogen Identified as a Key Ligand of ADAMTS13 through Optimized Plasma BioID • This study optimized the BioID proximity-dependent biotinylation technique for use in plasma to identify novel ligands of ADAMTS13, a metalloprotease crucial for regulating Von Willebrand Factor (VWF) activity and preventing thrombosis. • The optimized plasma BioID method, which addressed ATP instability in plasma by serial ATP supplementation, identified 108 proteins significantly interacting with ADAMTS13, including VWF (a positive control) and plasminogen. • Further investigation revealed that plasminogen, in its Glu- and Lys-forms, binds to ADAMTS13 with high affinity, specifically interacting with the C-terminus of ADAMTS13, involving the kringle domains of plasminogen and the Tsp-1 repeats or CUB domains of ADAMTS13. • The binding of plasminogen to ADAMTS13 was shown to be lysine-dependent, as it was attenuated by the lysine analogs tranexamic acid (TXA) and ε-aminocaproic acid (EACA). • Importantly, TXA also protected ADAMTS13 from degradation by plasmin, the active form of plasminogen, highlighting the role of this interaction in regulating ADAMTS13 activity. • Apolipoprotein(a) (apo(a)), sharing sequence homology with plasminogen, also bound to ADAMTS13 in a lysine-dependent manner, further supporting the significance of lysine residues in this interaction. • This research demonstrates the successful application of optimized plasma BioID to uncover crucial protein-protein interactions in the complex environment of plasma and provides valuable insights into the regulation of ADAMTS13 activity, which is crucial for maintaining hemostasis. https://lnkd.in/dTkWUmeJ

Immune-mediated and autoimmune diseases involving the oral mucosa, such as recurrent aphthous stomatitis (RAS), oral lichen planus (OLP), membrane mucous pemphigoid and pemphigus vulgaris, are often associated with painful intraoral ulcers, which can impair the patient oral functions, reducing the quality of life and sociability. We are working to face them and I’m happy to share one of our recent paper published on JDDST. See the article at: https://lnkd.in/gQdiw3Vt We described here an innovative technology based on Bilayer chitosan patches for steroidal drug delivery on the oral mucosa. The research has been carried out at the Departments of Health Sciences, and Translational Medicine, Center for Translational Research on Autoimmune and Allergic Diseases CAAD, Università del Piemonte Orientale (UPO), Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, National Interuniversity Consortium of Materials Science and Technology (INSTM), Department of Chemistry, Materials and Chemical Engineering “G. Natta”, Politecnico di Milano, Italy. Follow us! at #theinnovationlab.it

A new paper from my PhD 😊 Thanks Daniel and Naiem for advancing this paper towards publication!

The systemic delivery of Etodolac (ETO) often triggers side effects and exhibits unfavourable physicochemical properties, compelling the need for chronic dosing which could aggravate the condition. The transdermal route not only avoids the systemic toxicity but also enables site-specific action. Yet, the efficacy of this route is constrained due to skin barriers. In the present work, a choline geranate ionic liquid based transdermal gel (CAGE Ionogel) was prepared to improve permeation of ETO. The solubility of ETO increased by ~19,600-fold in CAGE IL than water. Moreover, ETO-CAGE Ionogel displayed sustained release for up to 48 h. The ex vivo permeation study revealed a higher flux (~1.3-fold) than ETO gel. The in-vitro and iv-vivo studies revealed a decrease in clinical signs of RA. X-ray imaging displayed reduced bone erosion and swelling. The findings affirm the efficacy of transdermal ETO therapy in alleviating RA manifestations. #researchpaper [3]